VIR - Vir Biotechnology, Inc.
| Previous close | 34.18 |
| Open | 34.00 |
| Bid | 35.61 x 1200 |
| Ask | 35.67 x 800 |
| Day's range | 33.84 - 35.90 |
| 52-week range | 11.65 - 75.00 |
| Volume | 873,400 |
| Avg. volume | 1,267,146 |
| Market cap | 4.202B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -14.64 |
| Earnings date | 12 May 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 34.33 |
- Motley Fool
3 Biotech Quick Picks to Invest $5,000 This Week
Gilead's stock has posted consistent growth this year as a result of its ambitious antiviral drug development program for COVID-19. With the preliminary publication of favorable clinical trial results for Gilead's remdesivir antiviral, the company cemented its earlier growth for the short term. On Thursday, Roche revealed that it was testing Gilead's remdesivir as part of a combination therapy for COVID-19, a move which will doubtlessly be followed by others in the coming weeks.
- Motley Fool
Vir Biotechnology Is Bucking The Biotech COVID-19 Trends, And Stands To Win
The company is an aggressive newcomer to the infectious-disease market and its COVID-19 programs are very promising.
- Motley Fool
Better Coronavirus Stock: Gilead Sciences or Vir Biotechnology?
These biotech companies are both infectious disease experts and are likely to remain in the forefront when it comes to coronavirus treatment.
- Motley Fool
Why Vir Biotechnology Rocketed Higher Today
Shares of Vir Biotechnology (NASDAQ: VIR) soared on Monday after the company announced some exciting news regarding its efforts to develop a treatment for COVID-19. Specifically, promising research findings from Vir's attempts to defeat COVID-19 were published in a paper in the journal Nature, one of the world's leading science journals. Vir's stock closed the day up by 32.1%.
- Simply Wall St.
Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Vir Biotechnology, Inc. (NASDAQ:VIR) came out with its quarterly results last week, and we wanted to see how the...
- Motley Fool
Vir Biotechnology and Alnylam Pick a Coronavirus Vaccine Candidate to Pursue
The partners will develop VIR-2703, which has the potential to prevent COVID-19, and also to treat it.
- Reuters
Vir, Alnylam identify COVID-19 therapy candidate, plan human trials by year end
The companies plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory authorities to discuss accelerating their filing for starting the trials of the inhaled therapy. Shares of Vir Biotech climbed 4% to $29, while Alnylam's stock rose 1.6% to $131 in premarket trading.
- Reuters
Vir, Alnylam plan human trials by year-end for potential COVID-19 therapy
The are currently no approved treatments or vaccine for COVID-19, the disease caused by the new coronavirus that has infected over 3.5 million and claimed nearly 247,000 lives. The companies' therapy candidate, VIR-2703, takes a new approach to potentially treating the virus by using RNA interference (RNAi) technology that targets and silences specific genetic material, blocking the production of deadly proteins that cause diseases. Alnylam specializes in developing RNAi drugs and currently has two FDA-approved drugs, Givlaari and Onpattro, for treating rare genetic diseases.
- Business Wire
Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19
Vir Biotechnology, Inc. (Nasdaq: VIR) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced the selection of a development candidate (DC) for VIR-2703 (also referred to as ALN-COV), an investigational RNAi therapeutic targeting the SARS-CoV-2 genome. The companies plan to soon meet with the U.S. Food and Drug Administration (FDA) and other regulatory authorities to discuss a potential accelerated path for filing an Investigational New Drug (IND) or IND equivalent application at or around year-end 2020, less than a year since program initiation. The companies plan to advance VIR-2703 as an inhalational formulation for the potential treatment and/or prevention of COVID-19.
- Zacks
Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
- Zacks
Glaxo to Buy Stake in Vir Biotech, Signs Coronavirus Deal
Glaxo (GSK) set to invest $250 million in Vir Biotechnology. Vir's stock soars.
- Reuters
GSK to partner with Vir for potential COVID-19 treatments, invest $250 million
Vir's shares rose as much as 34% following the news of GSK's investment, priced at $37.73 per Vir share, a 30% premium to the stock's Friday close. Vir's shares, trading at $35.60 on Monday, have more than doubled in the year up to Friday's close. Drugmakers across the globe are rushing to develop a treatment or vaccine for the fast-spreading coronavirus that has killed over 68,400 people globally.
- Business Wire
Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19
Generation Bio and Vir Biotechnology announce a collaborative research agreement.
- Zacks
Biotech Stocks Accelerate Efforts for Coronavirus Treatments
Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.
- Zacks
Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
- Zacks
LYFT, SIX, VIR, RDHL and KMDA as Zacks Bull and Bear of the Day
LYFT, SIX, VIR, RDHL and KMDA as Zacks Bull and Bear of the Day
- Zacks
Coronavirus Drug Development Efforts Pick Up Amid Sell-Off
Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.
- Zacks
3 Small Biotechs Provide Coronavirus Drug Development Updates
Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.
- Zacks
Vir (VIR) Looks Good: Stock Adds 12.9% in Session
Vir (VIR) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.
- Zacks
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals
- Zacks
Alnylam, Vir Collaborate on RNAi Therapy for Coronavirus
Alnylam (ALNY) expands its collaboration pact with Vir Biotechnology to develop RNAi therapeutics targeting SARS-CoV-2, the virus that induces Covid-19. Stock gains.
- Zacks
House Okays $8 Billion Funds to Combat COVID-19: 3 Winners
U.S. lawmakers' deal to find a vaccine for tackling the coronavirus stands to benefit the healthcare industry.
- Yahoo Finance
Coronavirus update: Markets rally, but infections creep closer to 100K amid spike in cases outside China
The global coronavirus outbreak has shown no signs of slowing down, with the worldwide total of new cases topping 94,000 and claiming over 3,200 lives.
